Abstract
RATIONALE: In patients with severe persistent asthma treated with high-dose inhaled corticosteroids (ICS), the ICS therapeutic margin ideally should be wide. Ciclesonide (CIC), a novel ICS with high lung deposition (~52%) and low bioavailability (<1%), may fulfill this criteria. CIC is mainly converted in the lung to its active metabolite, desisobutyryl-ciclesonide, which possesses high serum protein binding.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
